Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 11/20 | 0.34 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | PRKCA | P17252 | 1/20 | 0.34 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.33 |
| ▸ | FBP1 | P09467 | 3/20 | 0.33 |
| ▸ | ERBB2 | P04626 | 3/20 | 0.33 |
| ▸ | GAK | O14976 | 2/20 | 0.33 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.33 |
| ▸ | TNF | P01375 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | SRC | P12931 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094054 | 0.89 | PDGFRB (0.48) | PDGFRBEGFRABL1FBP1ERBB2 | |
| SCHEMBL3070313 | 0.89 | PDGFRB (0.48) | PDGFRBEGFRABL1FBP1ERBB2 | |
| SCHEMBL3070309 | 0.89 | PDGFRB (0.48) | PDGFRBEGFRABL1FBP1ERBB2 | |
| SCHEMBL4046330 | 0.88 | LCK (0.37) | PDGFRBEGFRABL1NTRK1FBP1 | |
| SCHEMBL4045102 | 0.87 | PDGFRB (0.39) | PDGFRBEGFRABL1PRKCAKDM4E | |
| SCHEMBL4043369 | 0.86 | FBP1 (0.47) | PDGFRBEGFRABL1PRKCAFBP1 | |
| SCHEMBL4045418 | 0.85 | CHEK1 (0.36) | MAPTMKNK1CHEK1 | |
| SCHEMBL4042472 | 0.82 | CHEK1 (0.33) | PDGFRBNTRK1GAKMKNK1CHEK1 | |
| SCHEMBL4042950 | 0.81 | PDGFRB (0.46) | PDGFRBEGFRABL1FBP1ERBB2 | |
| SCHEMBL4050643 | 0.80 | GRM4 (0.41) | PDGFRBEGFRFBP1ERBB2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| US-7795440-B2 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHARMACEUTICA NV (BE) | 2010-09-14 | — | — | US | disclosed |
| EP-1506175-B1 | N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-01 | — | — | EP | disclosed |
| CN-100396670-C | N-substituted 3-aminobenzene-pyrazoles as PDFG receptor inhibitors, pharmaceutical compositions and uses | JANSSEN PHARMACEUTICA NV (BE) | 2008-06-25 | — | — | CN | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | HO CHIH Y | 2007-06-21 | — | — | US | disclosed |
| US-7196110-B2 | N-substituted tricyclic 3-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | JANSSEN PHAMACEUTICA N.V. (BE) | 2007-03-27 | — | — | US | disclosed |
| CN-1668601-A | N-substituted tricyclic 3-aminopyrazoles as PDFG receptor inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2005-09-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142305-A1 | N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders | PDGFRA, PDGFRB, PDGFA | PDGFRB 2/4885EGFR 26/4885ABL1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.